# KORU Medical Systems, Inc.: overview KRMD · Nasdaq · CIK 704440 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/krmd.md) · [Financials](/companies/krmd/financials.md) · [Filings](/companies/krmd/filings.md) · [Insiders](/companies/krmd/insiders.md) Latest reported revenue: [$12.0m](/filings/0001161697-26-000189.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:Revenues, accession 0001161697-26-000189). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [8.2](/filings/0001161697-25-000372.md) | [8.8 d](/filings/0001161697-26-000052.md) | [9.6](/filings/0001161697-26-000108.md) | [10.2](/filings/0001161697-26-000189.md) | [10.4](/filings/0001161697-25-000372.md) | [10.9 d](/filings/0001161697-26-000052.md) | [11.8](/filings/0001161697-26-000108.md) | [12.0](/filings/0001161697-26-000189.md) | | Gross margin | % | [63.4%](/filings/0001161697-25-000372.md) | [62.9% d](/filings/0001161697-26-000052.md) | [62.8%](/filings/0001161697-26-000108.md) | [63.5%](/filings/0001161697-26-000189.md) | [60.2%](/filings/0001161697-25-000372.md) | [62.6% d](/filings/0001161697-26-000052.md) | [61.5%](/filings/0001161697-26-000108.md) | [65.1%](/filings/0001161697-26-000189.md) | | Operating margin | % | [(20.8%)](/filings/0001161697-25-000372.md) | [(18.0%) d](/filings/0001161697-26-000052.md) | [(12.9%)](/filings/0001161697-26-000108.md) | [(3.1%)](/filings/0001161697-26-000189.md) | [(8.3%)](/filings/0001161697-25-000372.md) | [(5.0%) d](/filings/0001161697-26-000052.md) | [(7.4%)](/filings/0001161697-26-000108.md) | [5.2%](/filings/0001161697-26-000189.md) | | Net margin | % | [(19.3%)](/filings/0001161697-25-000372.md) | [(17.7%) d](/filings/0001161697-26-000052.md) | [(12.1%)](/filings/0001161697-26-000189.md) | [(2.0%)](/filings/0001161697-26-000189.md) | [(7.5%)](/filings/0001161697-25-000372.md) | [(4.5%) d](/filings/0001161697-26-000052.md) | [(6.9%)](/filings/0001161697-26-000189.md) | [2.1%](/filings/0001161697-26-000189.md) | | Diluted EPS | $ per share | [0.03](/filings/0001161697-25-000372.md) | not reported | [(0.03)](/filings/0001161697-26-000108.md) | [0.00](/filings/0001161697-26-000189.md) | [0.02](/filings/0001161697-25-000372.md) | not reported | [(0.02)](/filings/0001161697-26-000108.md) | [0.01](/filings/0001161697-26-000189.md) | | Free cash flow | $m | [(2.0) d](/filings/0001161697-25-000372.md) | [0.9 d](/filings/0001161697-26-000052.md) | [(0.7)](/filings/0001161697-26-000108.md) | [(0.5) d](/filings/0001161697-26-000189.md) | [0.0 d](/filings/0001161697-25-000372.md) | [0.7 d](/filings/0001161697-26-000052.md) | [(0.0)](/filings/0001161697-26-000108.md) | [0.1 d](/filings/0001161697-26-000189.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [23.5](/filings/0001161697-23-000158.md) | [27.9](/filings/0001161697-24-000139.md) | [28.5](/filings/0001161697-25-000103.md) | [33.6](/filings/0001161697-26-000052.md) | [41.1](/filings/0001161697-26-000052.md) | | Gross margin | % | [58.6%](/filings/0001161697-23-000158.md) | [55.1%](/filings/0001161697-24-000139.md) | [58.6%](/filings/0001161697-25-000103.md) | [63.4%](/filings/0001161697-26-000052.md) | [62.3%](/filings/0001161697-26-000052.md) | | Operating margin | % | [(29.9%)](/filings/0001161697-23-000158.md) | [(38.6%)](/filings/0001161697-24-000139.md) | [(36.0%)](/filings/0001161697-25-000103.md) | [(19.2%)](/filings/0001161697-26-000052.md) | [(7.2%)](/filings/0001161697-26-000052.md) | | Net margin | % | [(19.4%)](/filings/0001161697-23-000158.md) | [(31.0%)](/filings/0001161697-24-000139.md) | [(48.2%)](/filings/0001161697-25-000103.md) | [(18.0%)](/filings/0001161697-26-000052.md) | [(6.4%)](/filings/0001161697-26-000052.md) | | Diluted EPS | $ per share | [(0.10)](/filings/0001161697-23-000158.md) | [(0.19)](/filings/0001161697-24-000139.md) | [(0.30)](/filings/0001161697-25-000103.md) | [(0.13)](/filings/0001161697-26-000052.md) | [(0.06)](/filings/0001161697-26-000052.md) | | Free cash flow | $m | [(4.7)](/filings/0001161697-23-000158.md) | [(8.2)](/filings/0001161697-24-000139.md) | [(5.7)](/filings/0001161697-25-000103.md) | [(1.6)](/filings/0001161697-26-000052.md) | [(0.5)](/filings/0001161697-26-000052.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/krmd/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [First Light Asset Management, LLC](/funds/1600004.md) | 2026-06-30 | $14.2m | 3,387,902 | | Reduced −380,478 | | [Topline Capital Management, LLC](/funds/1792549.md) | 2026-06-30 | $14.2m | 3,373,842 | | Reduced −141,069 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $11.0m | 2,628,352 | | Added +256,526 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $7.6m | 1,818,121 | | Added +131,897 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $4.7m | 1,128,096 | | Added +76,888 | | [Simcoe Capital LLC](/funds/2109203.md) | 2026-06-30 | $3.5m | 827,393 | | Added +16,146 | | [Meros Investment Management, LP](/funds/1911372.md) | 2026-06-30 | $3.2m | 759,664 | | Reduced −787 | | [Lionhunter Capital Management, LLC](/funds/2137268.md) | 2026-06-30 | $2.9m | 693,139 | | Not compared | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $2.7m | 646,572 | | Reduced −2,657 | | [Archon Capital Management LLC](/funds/1398825.md) | 2026-06-30 | $2.7m | 642,923 | | Unchanged | ## Recent filings [All 858 filings](/companies/krmd/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-14 | 20:01 ET | [8-K](/filings/0001161697-26-000200.md) | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001161697-26-000200 | | 2026-08-05 | 20:08 ET | [10-Q](/filings/0001161697-26-000189.md) | Quarterly report, period 2026-06-30 | 0001161697-26-000189 | | 2026-08-05 | 20:04 ET | [8-K](/filings/0001161697-26-000188.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001161697-26-000188 | | 2026-06-30 | 20:57 ET | [8-K](/filings/0001161697-26-000139.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001161697-26-000139 | | 2026-05-21 | 20:11 ET | [8-K](/filings/0001161697-26-000128.md) | 5.07 Shareholder vote results | 0001161697-26-000128 | | 2026-05-06 | 20:04 ET | [10-Q](/filings/0001161697-26-000108.md) | Quarterly report, period 2026-03-31 | 0001161697-26-000108 | | 2026-05-06 | 20:02 ET | [8-K](/filings/0001161697-26-000107.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001161697-26-000107 | | 2026-04-09 | 20:03 ET | [DEF 14A](/filings/0001161697-26-000091.md) | Proxy statement, period 2025-12-31 | 0001161697-26-000091 | | 2026-04-03 | 20:00 ET | [8-K](/filings/0001161697-26-000086.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001161697-26-000086 | | 2026-03-16 | 01:44 ET | [8-K](/filings/0001161697-26-000055.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001161697-26-000055 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001161697-26-000052.md), filed Mar 12, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/ecb418d9-43c7-4985-a557-427c53f418f1) ## About the filer - CIK: 704440 - Tickers: KRMD - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:22 ET. No prices; not investment advice.